Project Grant R21HL091268

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $306,870 to Kinetiq Therapeutics LLC, a life science startup in Texas, to conduct proof-of-concept studies on an enzyme replacement therapy (ERT) for Fanconi anemia. Fanconi anemia is a rare inherited disease characterized by bone marrow failure and malignancies. The project aims to demonstrate the feasibility of using an...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease. The project aims to test a novel lentiviral vector technology for efficiently editing hematopoietic stem cells to knockout the BCL11A enhancer, a key genetic target for sickle cell treatment. Through in vitro assays, the Phase I effort will...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is providing $827,942.00 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to investigate a novel inhibitory receptor that regulates the persistence and function of chimeric antigen receptor (CAR)-engineered T cell therapy for lymphoma. The key objectives are to: 1) examine the causal role of this inhibitory receptor axis in impairing the therapeutic...

The Project Grant award of $858,186, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to decipher the mechanisms leading to immune checkpoint inhibitor (ICI)-induced myocarditis and identify better mitigation strategies. The research leverages preliminary single-cell RNA sequencing data to analyze T cell clonotypes, biology, and predictive biomarkers associated with this fatal...

The National Heart Lung and Blood Institute (NHLBI) awarded a $814,209 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the Fred Hutchinson Cancer Center in Seattle, Washington. The grant supports research on developing CD90-targeted nanoparticles for in vivo hematopoietic stem cell gene therapy to treat genetic blood diseases and disorders. The project aims to refine the target for hematopoietic stem cell gene therapy and investigate the use of polymeric and...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a targeted therapy for acute myeloid leukemia (AML) with the chromosome inversion inv(16). The $545,170 award to Versiti Wisconsin, Inc. aims to characterize the mechanisms by which the oncogenic fusion protein CBFB-SMMHC activates the translation initiation factor EIF4G1, leading to AML transformation. The research will test whether inhibiting EIF4G1 can overcome...

Federal Grant Award Summary The University of Pennsylvania received a $810,875 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on June 15, 2025, with a completion date of March 31, 2029. This grant funds research to develop selective B cell depletion therapy using engineered T cells as a curative treatment for immune thrombotic thrombocytopenic purpura (ITTP), a life-threatening thrombotic...

This $683,472 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Cincinnati to develop a novel targeted therapy for acute myeloid leukemia (AML). The key objectives are to therapeutically target the DHODH enzyme to induce AML cell differentiation, activate the immune system, and induce ferroptosis-mediated cell death. This approach aims to better differentiate AML cells from normal hematopoietic stem cells and enhance...

Grant Award Summary Immunomatics, Inc. received a $207,740 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 15, 2025, with completion targeted for July 31, 2026. The project delivers a machine learning-based prediction model designed to identify permissive human leukocyte antigen (HLA) mismatches in hematopoietic stem cell transplantation (HCT) recipients undergoing posttransplant...

The Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $778,092.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to advance preclinical studies of a dual-targeted fine-tuned immune-restoring (DFIR) CAR-T cell therapy for the treatment of high-grade serous ovarian cancer. This research aims to develop innovative immunotherapeutic approaches to achieve cures for this aggressive form of ovarian cancer. DFCI, a...